Global Infectious Disease Testing Device Market Size By Type (Molecular Diagnostic Test, POCT), By Application (Hospital, Clinic), By Region, And Segment Forecasts, 2023 to 2032

The Global Infectious Disease Testing Device Market was valued at USD 22.6 billion in 2023 and is projected to reach USD 41.9 billion by 2031, growing at a CAGR of 7.9% during the forecast period from 2023 to 2031. The demand for infectious disease testing devices is driven by the rising prevalence of infectious diseases worldwide, heightened awareness of early diagnostic testing, and continuous technological advancements in molecular diagnostics, point-of-care testing, and immunoassays. Public health initiatives and pandemic preparedness programs globally are further propelling the growth of the market.

Drivers:

1. Growing Burden of Infectious Diseases:

An increase in outbreaks of diseases such as tuberculosis, HIV/AIDS, influenza, and COVID-19 has amplified the demand for rapid and accurate diagnostic tools, boosting the infectious disease testing device market.

2. Technological Advancements in Diagnostics:

Innovations such as multiplex PCR, next-generation sequencing (NGS), CRISPR-based diagnostics, and AI-powered analysis are transforming the infectious disease detection landscape, enabling faster and more precise results.

3. Rising Demand for Point-of-Care Testing:

The convenience and speed of point-of-care testing devices, especially in remote and resource-limited settings, are increasingly favored by healthcare providers and patients, leading to widespread market adoption.

Restraints:

1. High Cost of Advanced Diagnostic Devices:

The elevated cost associated with state-of-the-art testing equipment and consumables can be a limiting factor for adoption, especially in low- and middle-income countries.

2. Regulatory and Reimbursement Challenges:

Strict regulatory pathways and inconsistent reimbursement policies across countries may delay the commercialization and uptake of innovative testing devices.

Opportunity:

1. Market Penetration in Emerging Economies:

Countries across Asia-Pacific, Latin America, and Africa are increasingly investing in healthcare infrastructure, creating significant growth opportunities for infectious disease diagnostic technologies.

2. Integration with Digital Health Platforms:

Combining diagnostic devices with telehealth, electronic medical records (EMR), and mobile health apps offers an opportunity to enhance access, traceability, and patient management.

Market by System Type Insights:

The Molecular Diagnostic Devices segment held the largest market share in 2023. Its high sensitivity, ability to detect multiple pathogens simultaneously, and application in both centralized and decentralized settings make it a preferred choice. However, the Rapid Diagnostic Tests (RDTs) segment is projected to witness the fastest growth owing to increasing demand for quick and accurate screening during outbreaks and in low-resource environments.

Market by End-use Insights:

In 2023, Hospitals and Diagnostic Laboratories accounted for the largest share due to their ability to handle high volumes of tests and complex diagnostics. Meanwhile, Homecare Settings and Clinics are expected to experience the highest growth rate due to the rising popularity of over-the-counter and at-home test kits, especially post-COVID-19.

Market by Regional Insights:

North America dominated the market in 2023, driven by advanced healthcare infrastructure, proactive disease surveillance programs, and strong presence of leading diagnostic companies. However, the Asia-Pacific region is projected to grow at the fastest rate during the forecast period due to increasing healthcare investments, improving access to diagnostics, and growing disease prevalence.

Competitive Scenario:

Key players operating in the Global Infectious Disease Testing Device Market include Abbott Laboratories, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., Siemens Healthineers, Becton, Dickinson and Company, bioMérieux SA, Cepheid, QuidelOrtho Corporation, and Qiagen N.V. These companies focus on product innovation, strategic partnerships, and expanding access in developing regions.

Key Developments:

In 2023, Abbott Laboratories launched a next-generation multiplex rapid test capable of detecting influenza A/B, RSV, and SARS-CoV-2 simultaneously.

In 2024, Roche Diagnostics expanded its global footprint by opening a new molecular diagnostics facility in India.

In 2025, Thermo Fisher Scientific introduced AI-integrated PCR platforms to enhance real-time diagnostic accuracy.

Scope of Work – Global Infectious Disease Testing Device Market

Report Metric Details

Market Size (2023) USD 22.6 billion

Projected Market Size (2031) USD 41.9 billion

CAGR (2023–2031) 7.9%

Market Segments System Type (Molecular Diagnostics, RDTs, Immunoassays), End-use (Hospitals, Laboratories, Homecare), Region

Growth Drivers Rise in infectious diseases, technological innovations, point-of-care demand

Opportunities Emerging markets, digital health integration

FAQs:

1) What is the current market size of the Global Infectious Disease Testing Device Market?

The market was valued at USD 22.6 billion in 2023.

2) What is the major growth driver of the Global Infectious Disease Testing Device Market?

The key driver is the increasing burden of infectious diseases and demand for rapid, accurate diagnostics.

3) Which is the largest region during the forecast period in the Global Infectious Disease Testing Device Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Infectious Disease Testing Device Market?

Molecular Diagnostic Devices led the market by system type in 2023.

5) Who are the key market players in the Global Infectious Disease Testing Device Market?

Major players include Abbott, Roche, Thermo Fisher Scientific, Bio-Rad, Siemens Healthineers, and Cepheid.